By Fineline Cube 
ACROBiosystems Co., Ltd. (SHE: 301080) and Bailinke Pharmaceutical Technology (Shanghai) Co., Ltd. have entered into a strategic partnership to establish a long‑term strategic relationship focused on AI‑empowered, next‑generation affinity purification ligands and affinity chromatography resins. The two companies will jointly build a next‑generation affinity purification solution that integrates “upstream AI protein design + downstream affinity resins.”
Deal Snapshot
| Item | Detail |
|---|---|
| Partners | ACROBiosystems Co., Ltd. (301080) & Bailinke Pharmaceutical Technology (Shanghai) Co., Ltd. |
| Agreement Type | Long‑term strategic partnership |
| Announcement Date | 13 Aug 2026 |
| Focus Areas | AI‑empowered affinity purification ligands; affinity chromatography resins |
| Integrated Solution | Upstream AI protein design + downstream affinity resins |
| Financial Terms | Not disclosed |
Technology Scope – AI‑Empowered Affinity Purification
- Core Objective: Develop next‑generation affinity purification ligands and affinity chromatography resins empowered by artificial intelligence.
- Integration Model: Combine upstream AI protein design with downstream affinity resins into a single, integrated affinity purification solution.
- Process Significance: Affinity purification is one of the most critical core processes in antibody and biopharmaceutical manufacturing; its technological level directly impacts production efficiency, product quality, and manufacturing costs.
Company Profile – ACROBiosystems
- Founded: 2010; listed on the ChiNext market in 2021 (Stock Code: 301080)
- Vision: To become a cornerstone platform enterprise providing critical biological reagents, solutions, and innovative business models for the global biopharmaceutical and healthcare industries
- Global Footprint: Operations across Asia, North America, and Europe, with offices, R&D centers, and manufacturing bases in 16 cities across countries including China, the United States, and Switzerland
Market Impact & Outlook
- AI Meets Downstream Processing: The partnership applies AI protein design to affinity ligands — an area where rational engineering has historically been slow — potentially accelerating ligand optimization and resin performance.
- Cost and Quality Leverage: Because affinity purification directly drives production efficiency, product quality, and manufacturing costs, improvements in ligand/resin technology carry direct commercial value for antibody and biopharmaceutical manufacturers.
- Platform Synergy: ACROBiosystems’ global reagent platform and manufacturing infrastructure complement Bailinke Pharmaceutical’s ligand engineering capabilities, creating an end‑to‑end solution from design to resin.
- Strategic Positioning: The integrated “design + resin” offering positions the partnership to serve the growing demand for cost‑effective, high‑quality downstream processing across the global biopharmaceutical industry.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the strategic partnership between ACROBiosystems and Bailinke Pharmaceutical, the development of AI‑empowered affinity purification solutions, and potential commercial applications. Actual results may differ due to risks including technology development timelines, market adoption, and competitive dynamics in biopharmaceutical process technologies.-Fineline Info & Tech